...
首页> 外文期刊>Gastroenterology >Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
【24h】

Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.

机译:HBeAg阳性慢性乙型肝炎患者急性加重期间早期HBeAg血清转变的预测因素。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND & AIMS: This study aimed to identify the predictors for early hepatitis B e antigen (HBeAg) seroconversion following acute exacerbation (AE) in patients with HBeAg-positive chronic hepatitis B (CHB). METHODS: A total of 151 patients with HBeAg-positive CHB and AE were consecutively enrolled. AE was defined as an elevation of alanine aminotransferase level to more than 5 times the upper limit of normal and more than twice the patients' baseline value. Early HBeAg seroconversion was defined as HBeAg loss and the appearance of hepatitis B e antibody within 6 months of AE. Clinical and laboratory data were compared between an early HBeAg seroconversion group and a nonearly HBeAg seroconversion group. RESULTS: All patients had genotype C hepatitis B virus (HBV). Early HBeAg seroconversion occurred in 35.5% (39/110). Under univariate analysis, age, transmission mode, disease status, and serum HBV DNA level were associated with early HBeAg seroconversion. Multivariate analysis showed that nonvertical transmission mode (RR, 3.681; 95% CI, 1.279-10.592; P = .016) and low serum HBV DNA levels (< or = log [copies/mL]; RR, 6.891; 95% CI, 2.165-21.935; P = .001) were independent predictors. CONCLUSIONS: Patients with CHB with genotype C may have a higher chance of early HBeAg seroconversion after AE in the context of nonvertical transmission and/or had low serum HBV DNA levels (< or = 7 log [copies/mL]) at AE. Therefore, we should take into account transmission modes and serum HBV DNA levels when choosing appropriate management strategies for patients who exhibit AE of HBeAg-positive CHB with genotype C.
机译:背景与目的:本研究旨在确定HBeAg阳性慢性乙型肝炎(CHB)患者急性加重(AE)后早期乙型肝炎e抗原(HBeAg)血清转化的预测因素。方法:共纳入151例HBeAg阳性CHB和AE患者。 AE被定义为丙氨酸转氨酶水平升高至正常上限的5倍以上和患者基线值的两倍以上。早期HBeAg血清转化定义为AE 6个月内HBeAg丢失和乙肝e抗体出现。比较早期HBeAg血清转化组和早期HBeAg血清转化组的临床和实验室数据。结果:所有患者均具有基因型C型乙型肝炎病毒(HBV)。早期HBeAg血清转化发生率为35.5%(39/110)。在单因素分析下,年龄,传播方式,疾病状况和血清HBV DNA水平与早期HBeAg血清转化有关。多变量分析显示,非垂直传播模式(RR,3.681; 95%CI,1.279-10.592; P = .016)和低血清HBV DNA水平(<或= log [copies / mL]; RR,6.891; 95%CI, 2.165-21.935; P = .001)是独立的预测因子。结论:基因型C的CHB患者在非垂直传播的情况下,AE后发生早期HBeAg血清学转换的机会更高,和/或在AE中血清HBV DNA水平较低(<或= 7 log [拷贝/ mL])。因此,对于表现为C基因型HBeAg阳性CHB AE的患者,选择适当的治疗策略时,应考虑到传播方式和血清HBV DNA水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号